Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone furoate
Drug ID BADD_D00946
Description Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Indications and Usage Fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
Marketing Status approved
ATC Code R01AD12; R03BA09
DrugBank ID DB08906
KEGG ID D06315
MeSH ID C523187
PubChem ID 9854489
TTD Drug ID D0Y7JU
NDC Product Code 47848-057; 64918-1915; 0135-0615; 64918-1910; 64918-1916; 22552-0042; 63379-083; 55018-302; 58175-0553; 0135-0616; 63592-3370; 0173-0874; 0173-0888; 50090-5967; 49076-6452; 59057-010; 0173-0876; 50090-6075; 15308-2021; 52482-008; 63379-084; 49076-6451; 59057-009; 64918-1117
UNII JS86977WNV
Synonyms fluticasone furoate
Chemical Information
Molecular Formula C27H29F3O6S
CAS Registry Number 397864-44-7
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Thrombosis24.01.01.006--Not Available
Tongue coated07.14.02.011--Not Available
Toothache07.09.06.001--
Tremor17.01.06.002--
Ulcer08.03.06.001--Not Available
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.0010.001345%
Visual acuity reduced06.02.10.012; 17.17.01.0110.000611%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.000611%
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Wheezing22.03.01.0090.002262%
Intervertebral disc protrusion15.10.01.004--Not Available
Rhinalgia22.12.03.020--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Nasal discomfort22.12.03.012--Not Available
Secretion discharge08.01.03.019--Not Available
Growth retardation05.03.02.007; 15.03.05.016; 14.03.02.0310.000917%
Haemorrhage24.07.01.0020.000917%Not Available
Pulmonary mass22.02.07.004--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Mediastinal disorder22.09.03.001--Not Available
Ill-defined disorder08.01.03.049--Not Available
Adverse drug reaction08.06.01.009--Not Available
Disease recurrence08.01.03.050--Not Available
Obstructive airways disorder22.03.01.011--Not Available
Sinus disorder22.04.06.002--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages